SMSLIFE
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
SMS Lifesciences India soars; facility gets US FDA clearance
** SMS Lifesciences India SMSL.NS soars 17% to 1,342.2 rupees; set to snap four sessions of losses
** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in Telangana gets establishment inspection report from U.S. FDA with "voluntary action indicated" (VAI)
** A VAI classification implies facility won't face any regulatory action
** SMSL, which jumped 17% prior to the news, held gains after company disclosure
** Stock set for best day since August 12, 2024
** SMSL moved above its 50-day, 100-day, 200-day simple moving avgs
** Stock sees most active session since August 12, 2024, with more than 82,000 shares traded - 70x the 30-day moving avg
** YTD, SMSL gains 13.4%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
** SMS Lifesciences India SMSL.NS soars 17% to 1,342.2 rupees; set to snap four sessions of losses
** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in Telangana gets establishment inspection report from U.S. FDA with "voluntary action indicated" (VAI)
** A VAI classification implies facility won't face any regulatory action
** SMSL, which jumped 17% prior to the news, held gains after company disclosure
** Stock set for best day since August 12, 2024
** SMSL moved above its 50-day, 100-day, 200-day simple moving avgs
** Stock sees most active session since August 12, 2024, with more than 82,000 shares traded - 70x the 30-day moving avg
** YTD, SMSL gains 13.4%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Haleos Labs do?
SMS Lifesciences India is involved in the manufacturing, buying, selling, and consultancy of Organic & Inorganic Chemicals, Pharmaceuticals, API, and Intermediates.
Who are the competitors of Haleos Labs?
Haleos Labs major competitors are Nectar Lifesciences, Everest Organics, Smruthi Organics, Tyche Inds, Bal Pharma, Mangalam Drugs&Org., Shree Ganesh Remed.. Market Cap of Haleos Labs is ₹363 Crs. While the median market cap of its peers are ₹147 Crs.
Is Haleos Labs financially stable compared to its competitors?
Haleos Labs seems to be less financially stable compared to its competitors. Altman Z score of Haleos Labs is 2.85 and is ranked 4 out of its 8 competitors.
Does Haleos Labs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Haleos Labs latest dividend payout ratio is 2.26% and 3yr average dividend payout ratio is 3.73%
How has Haleos Labs allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Accounts Receivable
How strong is Haleos Labs balance sheet?
Balance sheet of Haleos Labs is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Haleos Labs improving?
The profit is oscillating. The profit of Haleos Labs is ₹16.02 Crs for TTM, ₹20.11 Crs for Mar 2025 and ₹9.09 Crs for Mar 2024.
Is the debt of Haleos Labs increasing or decreasing?
The net debt of Haleos Labs is decreasing. Latest net debt of Haleos Labs is ₹81.08 Crs as of Mar-25. This is less than Mar-24 when it was ₹94.79 Crs.
Is Haleos Labs stock expensive?
Yes, Haleos Labs is expensive. Latest PE of Haleos Labs is 21.0, while 3 year average PE is 18.17. Also latest EV/EBITDA of Haleos Labs is 11.01 while 3yr average is 9.87.
Has the share price of Haleos Labs grown faster than its competition?
Haleos Labs has given better returns compared to its competitors. Haleos Labs has grown at ~13.35% over the last 8yrs while peers have grown at a median rate of 0.26%
Is the promoter bullish about Haleos Labs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Haleos Labs is 71.41% and last quarter promoter holding is 71.41%.
Are mutual funds buying/selling Haleos Labs?
There is Insufficient data to gauge this.
